A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

BACKGROUND: This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. OBJECTIV...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Target Oncol
Autori principali: Wainberg, Zev A., Alsina, Maria, Soares, Heloisa P., Braña, Irene, Britten, Carolyn D., Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A., Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J., Siu, Lillian L., Vermette, Jennifer, Tabernero, Josep
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2017
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700209/
https://ncbi.nlm.nih.gov/pubmed/29067643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0530-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi